Strongbridge Biopharma

Strongbridge Biopharma: Commercial stage company focused on rare diseases (incl. Cushing's disease & primary periodic paralysis). Exp RECORLEV® submission in Q121 following positive top-line data from LOGICS Study in Q320. Launch exp Q122, following ~10-mo PDUFA cycle. FY 2020 KEVEYIS® revenue fuidance of $28-$29m. Increased cash position Sept 2020; ext runway beyond Q1 2023.
Based in...
US - Middle Atlantic
Clinical Stage
Disease Space
Central Nervous System, Diagnostics, Metabolic Disorders, Rare Disease
Public, USA
Market Cap
100MM - 500MM
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
United States

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

John Johnson
Strongbridge Biopharma, CEO
John has served as chairman of our board of directors since March 2015. He is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer, Inc. He currently serves as executive chairman of VirMedica, lead independent director of Sucampo Pharmaceuticals, Inc., and as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation, and Portola Pharmaceuticals, Inc. John previously served on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.

Top 10 Holders of Strongbridge Biopharma plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Caxton Corp. 14.92 8,089,442 26.86 13F 12/31/20
NEA Management Co. 7.64 4,141,308 13.75 13F 12/31/20
OrbiMed Advisors LLC 5.51 2,986,869 9.92 Stakes 12/31/20
Ikarian Capital LLC 4.50 2,440,028 8.10 13F 12/31/20
Renaissance Technologies LLC 4.04 2,189,200 7.27 13F 12/31/20
The Vanguard Group, Inc. 3.95 2,139,064 7.10 Funds 1/31/21
Vanguard Group, Inc. (Subfiler) 3.61 1,957,256 6.50 13F 12/31/20
Morgan Stanley Smith Barney LLC 3.54 1,918,019 6.37 13F 12/31/20
AIGH Capital Management LLC 3.25 1,764,173 5.86 13F 12/31/20
683 Capital Management LLC 2.94 1,595,082 5.30 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.